Jasper Therapeutics, Inc. (JSPR)
- Previous Close
20.76 - Open
20.61 - Bid 20.91 x 200
- Ask 21.76 x 100
- Day's Range
20.61 - 21.68 - 52 Week Range
4.00 - 31.01 - Volume
20,398 - Avg. Volume
100,009 - Market Cap (intraday)
320.569M - Beta (5Y Monthly) 2.25
- PE Ratio (TTM)
-- - EPS (TTM)
-61.80 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
67.00
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
www.jaspertherapeutics.com/Recent News: JSPR
Performance Overview: JSPR
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JSPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JSPR
Valuation Measures
Market Cap
313.18M
Enterprise Value
229.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.99
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-60.09%
Return on Equity (ttm)
-112.67%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-64.47M
Diluted EPS (ttm)
-61.80
Balance Sheet and Cash Flow
Total Cash (mrq)
86.89M
Total Debt/Equity (mrq)
3.55%
Levered Free Cash Flow (ttm)
-30.35M
Research Analysis: JSPR
Company Insights: JSPR
JSPR does not have Company Insights